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Abstract
Background: Heparanase, endoglycosidase that cleaves heparan sulfate side chains of heparan sulfate proteoglycans, plays
important roles in cancer metastasis, angiogenesis and inflammation.
Design and Methods: Applying a mouse model of bone marrow transplantation and transgenic mice over-expressing
heparanase, we evaluated the effect of heparanase on the engraftment process and the development of graft-versus-host
disease.
Results: Analysis of F1 mice undergoing allogeneic bone marrow transplantation from C57BL/6 mice demonstrated a better
and faster engraftment in mice receiving cells from donors that were pretreated with heparanase. Moreover, heparanase
treated recipient F1 mice showed only a mild appearance of graft-versus-host disease and died 27 days post transplantation
while control mice rapidly developed signs of graft-versus-host disease (i.e., weight loss, hair loss, diarrhea) and died after 12
days, indicating a protective effect of heparanase against graft-versus-host disease. Similarly, we applied transgenic mice
over-expressing heparanase in most tissues as the recipients of BMT from C57BL/6 mice. Monitoring clinical parameters of
graft-versus-host disease, the transgenic mice showed 100% survival on day 40 post transplantation, compared to only 50%
survival on day 14, in the control group. In vitro and in vivo studies revealed that heparanase inhibited T cell function and
activation through modulation of their cytokine repertoire, indicated by a marked increase in the levels of Interleukin-4,
Interleukin-6 and Interleukin-10, and a parallel decrease in Interleukin-12, tumor necrosis factor-alfa and interferon-gamma.
Using point mutated inactive enzyme, we found that the shift in cytokine profile was independent of heparanase enzymatic
activity.
Conclusions: Our results indicate a significant role of heparanase in bone marrow transplantation biology, facilitating
engraftment and suppressing graft-versus-host disease, apparently through an effect on T cell activation and cytokine
production pattern.
Citation: Bitan M, Weiss L, Zeira M, Zcharia E, Slavin S, et al. (2010) Heparanase Promotes Engraftment and Prevents Graft versus Host Disease in Stem Cell
Transplantation. PLoS ONE 5(4): e10135. doi:10.1371/journal.pone.0010135
Editor: Derya Unutmaz, New York University, United States of America
Received February 18, 2010; Accepted March 16, 2010; Published April 15, 2010
Copyright:  2010 Bitan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the Israel Science Foundation (grant 549/06); National Cancer Institute (RO1-CA106456). I. Vlodavsky is a
Research Professor of the ICRF. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Vlodavsk@cc.huji.ac.il
¤ Current address: Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel
Introduction
Heparan sulfate proteoglycans (HSPGs) are ubiquitous macro-
molecules associated with the cell surface and extracellular matrix
(ECM) of a wide range of cells [1,2,3]. The basic HSPG structure
consists of a protein core to which several linear heparan sulfate
(HS) chains are covalently O-linked [1,2,3]. HS chains, unique in
their ability to bind a multitude of proteins, ensure that a wide
variety of bioactive molecules bind to the cell surface and ECM
and thereby function in the control of diverse normal and
pathological processes [1,4,5]. The majority of studies on cell
interaction with the microenvironment focused, among other
approaches, on proteolytic enzymes [6]. The involvement of
glycosaminoglycan (e.g., heparan sulfate) degrading enzymes (e.g.,
heparanase) was underestimated, primarily due to a lack of
appropriate molecular probes to explore their causative role in
cell-ECM interactions and related effects. A long-term research on
the biology of heparanase led to the cloning of a single gene
encoding a HS-degrading endoglycosidase (heparanase) which
plays important roles in cancer metastasis, angiogenesis and
inflammation [7,8,9,10,11,12,13,14,15,16,17]. Heparanase is syn-
thesized as a 65 kDa latent precursor that subsequently undergoes
proteolytic processing by cathepsin L [18,19], yielding 8 kDa and
50 kDa protein subunits that undergo heterodimerization to form
the active enzyme [20,21,22]. The enzyme has been identified in
invasive normal and malignant cells, including activated cells of
the immune system, cytotrophoblasts, keratinocytes, lymphoma,
melanoma, myeloma and carcinoma cells [7,8,9,10,11,12,13,14].
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accompanied by degradation of various components of the
subendothelial ECM. Activated immune cells produce and secrete
a variety of ECM degrading enzymes, including heparanase
[10,11,23,24,25]. Degradation of HS disintegrates the supramo-
lecular structure of the subendothelial basal lamina, consequently
facilitating trans-endothelial migration of neutrophils and activat-
ed lymphocytes, thereby mediating their extravasation during
immune responses [10,11,15,23,24,25]. Allogeneic hematopoietic
stem cell transplantation (SCT) is a therapeutic modality in a
growing number of malignant and non-malignant diseases. It
provides a powerful anti-tumor activity through the graft-versus-
leukemia/tumor effect mediated by donor T cells [26,27,28].
Since donor alloreactive T-cells are also being activated against
host epitopes presented on normal tissues, graft-versus-host disease
(GVHD) [29,30] is the most common threatening complication
post allogeneic transplantation.
We have recently demonstrated that heparanase modulates the
bone marrow (BM) microenvironment as well as basic features of
hematopoietic stem and progenitor cells, including development,
proliferation and retention [31]. We have also found a marked
increase in the number of hematopoietic stem cells in the BM of
heparanase over-expressing transgenic (Hpa-tg)m i c ec o m p a r e dt o
wild type (wt) control mice [31]. Moreover, a minimal dose of white
blood cells from the BM of hpa-tgmice, but not wt mice, was sufficient
to rescue lethality irradiated C57BL/6 recipient mice, indicating that
a higher number of hematopoietic repopulating cells exists in the BM
of the hpa-tg mice [31]. These results and the recently reported
protective effect of heparanase against autoimmune type-1 diabetes
[32] prompted us to investigate the effect of heparanase on
engraftment and GVHD in transplantation animal models.
In the GVHD process, antigen-specific CD4+ cells polarized
toward the Th1 phenotype mediate inflammatory damage in the
host body, resulting in tissue dysfunction, multi-organ failure and
high mortality rate [26,28,29,30]. On the other hand, increased
production of Th2 cytokines and a parallel suppression of Th1
cytokines, lead to amelioration of GVHD [28,33,34,35]. Mature T
cells infused with the bone marrow graft respond to alloantigens
and other changes in the allogeneic host tissues induced by the
pre-transplantaion conditioning. The injured host tissues produce
proinflammatory cytokines such as interleukin-2 (IL-2) and
interferon-gamma (IFN-c) which in turn activate donor effector
cells to release IL-1 and tumor necrosis factor-alfa (TNF-a),
further activating the alloreactive T cells, thereby causing direct
tissue destruction [36,37,38,39].
Our results indicate an enhancing effect of heparanase on
engraftment, as well as a protective activity against GVHD. The
anti-GVHD effect appears to be attributed to suppression of T cell
activation and a shift from a Th1 to Th2 cytokine profile.
Materials and Methods
Mice
Eight to 12 weeks old C57BL/6 (H-2
b) and (Balb/c x C57BL/6)
(H-2
d/b) F1 mice, male and female, were purchased from Harlan
Breeding Facility (Jerusalem, Israel). Heparanase overexpressing
C57BL/6 transgenic (hpa-tg) mice were previously described in
detail [40]. The heparanase transgene was introduced under the
actin promoter to drive overexpression of heparanase in most
tissues [40]. All mice were maintained in top filtered cages in a
standard animal facility. Cages, sawdust and water bottles were
autoclaved weekly. All the animal experiments were approved by
the animal committees of the Hebrew University, Jerusalem Israel
(MD-89.49-4) according to the NIH guidelines.
Conditioning by radiation
F1 and Hpa-tg mice were exposed to a sublethal (750 cGy) total
body irradiation by a linear accelerator (Varian Clinac 6X GC,
Palo Alto, CA) at a dose rate of 170 cGy/min, and a source-to-
skin distance of 80 cm [31].
Spleen cell preparation
Spleen cells from donor mice were suspended in PRMI 1640
medium supplemented with 10% fetal calf serum, glutamine
(2 mM), penicillin (100 U/ml) and streptomycin (100 mg/ml)
(Biological Industries, Beit-Haemek, Israel), washed twice and
resuspended in the same medium [41].
Transplantation design
One day following irradiation, F1 mice were transplanted
intravenously with 10610
6 allogeneic (C57BL/6) spleen cells.
Animals were divided into 4 groups (10 mice each): mice
transplanted with spleen cells obtained from C57BL/6 mice
pretreated with saline (3–5 days) followed by daily intraperitoneal
(i.p) injection of saline (group 1), or recombinant heparanase
(group 2), post transplantation; mice transplanted with spleen cells
obtained from C57BL/6 mice pretreated with heparanase (3–5
days, i.p.) followed by daily injection of saline (group 3), or
recombinant heparanase (group 4) for 7 days post transplantation.
The first injection was given 15 min before transplantation. In
another set of experiments, hpa-tg and wt mice were injected with
25610
6 or 50610
6 C57BL/6 splenocyes one day post irradiation.
One month after transplantation, the number of donor-type cells
present in the blood was determined by flow cytometry.
Chimerism was assessed by the ameloginin gene expression
method, as previously described [42].
Monitoring of GVHD
Recipient mice were monitored for clinical signs of GVHD
(ruffled fur, diarrhea, runt disease, weight loss) and survival, as
described [41].
Heparanase
Single-chain GS3 active heparanase gene construct, composed
of the 8 kDa and 50 kDa heparanase subunits, was kindly
provided by Dr. Christian Steinkuhler (IRMB/Merck Research
Laboratories, Pomezia, Italy) [22], and the protein was purified
from the conditioned medium of baculovirus infected cells, as
described [21,22]. Recombinant 65 kDa latent human hepar-
anase and inactive heparanase mutated in glutamic acid residues
225 and 343 that comprise the enzyme active site [43] were
purified from the culture medium of transfected HEK-293 cells,
as described [44]. Heparanase preparations were assayed for the
presence of bacterial endotoxin by Biological Industries (Beit
Haemek, Israel), using the gel-clot technique (Limulus amebocyte
lysate–LAL test) and were found to contain ,10 pg/ml
endotoxin.
Modified heparin
Compound ST1514 was kindly provided by Dr. Claudio Pisano
(Sigma-Tau, Research Department, Pomezia, Italy). Briefly,
heparin was subjected to controlled alkali-catalyzed removal of
sulfate groups of iduronic acid 2-O-sulfate residues, giving rise to
the corresponding epoxide derivative. The epoxide rings were
opened, followed by oxidative glycol-splitting of the newly formed
(and the preexisting) nonsulfated uronic acid residues [45,46]. The
ST1514 compound is 50% glycol-split modified heparin (H
50gs;
MW 11,200) [45,46].
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a) ConA. Mouse spleen cells were cultured in RPMI-1640
medium supplemented with 10% heat-inactivated human AB
serum in flat-bottomed 96-well microtiter plates (Nunc,
Wiesbaden, Germany) containing 0.5610
6 cells/well/0.2 ml.
Response to 2 mg/ml concanvalin-A (ConA, Sigma, St. Louis,
MO) was assessed by
3H-thymidine incorporation, as described
[47].
b) Mixed lymphocyte culture (MLC). Mouse spleen cells
were cultured in RPMI-1640 medium, supplemented with 10%
heat-inactivated human AB serum in 96-well flat-bottomed
microtiter plates (Nunc, Wiesbaden, Germany) containing 1610
6
responding cells and 1610
6 irradiated (3000 cGy) stimulating cells
per 0.2 ml well. Cells were cultured for 5 days in a 5% CO2
humidified incubator. Twenty hours before harvesting, 1 mCi
3H-
thymidine was added to each well and thymidine incorporation
was measured, as described [47].
Cytotoxicity assay
ConA activated splenocytes were co-cultured with 3–5610
6
target Yac (H-2
a, NK-sensitive tumor cell line) cells [48], with or
without active (5 mg/ml) or latent (30 mg/ml) heparanase in order
to evaluate their killing capacity. The Yac cells were first
incubated overnight with 5 ml
35S-methionine (Easytag methio-
nine, L-[
35S], TBq/mmol; Perkin Elmer Life Science, Boston,
MA) in RPMI medium without methionine. Cytotoxic activity
was measured in a 5 h
35S-release assay, as previously described
[48].
Cytokine analysis
In order to assess Th1 vs. Th2 cell phenotypes, medium from
C57BL/6-derived spleen lymphocytes, cultured for 24 h in the
absence or presence of heparanase, was subjected to ELISA
analysis of IL-4, IL-6, IL-10, IL-12, IFN-c and TNF-a,a s
described [38,39,41,49].
Statistics
Student’s t test was used for statistical analysis of the results.
Asterisk (*) indicates statistical difference (p,0.05). Two Asterisks
(**) indicate highly statistical differences (p,0.01).
Results
Effect of heparanase on engraftment
Heparanase facilitates release of ECM-bound growth factors
and chemokines via degradation of heparan sulfate [9,16]. Hence,
we investigated whether heparanase enhances engraftment of
hematopoietic cells. F1 mice were sublethally irradiated (750 cGy)
and transplanted with 10610
6 spleen cells derived from hepar-
anase (5 mg/mouse/day, i.p. for 3 days)- or saline (control)- treated
C57BL/6 mice. The recipients were injected with recombinant
heparanase (5 mg/mouse/day, i.p.) from the day of transplantation
until day +7. Control recipient mice were injected with saline
alone. Heparanase treatment of both the donor and recipient mice
resulted in a significant shortening of time to engraftment. The
mean WBC counts on day +14 post transplantation in the
heparanase treated mice was 1.36610
9/L (range 1.2–1.68610
9/
L), as compared to 0.48610
9 cells/L (range 0.3–0.74610
9/L) in
the control group (p,0.01). Significantly higher counts were
obtained after 3 weeks, 2.85610
9 cells/L (range 2.4–3.4610
9/L)
vs. 0.85610
9 cells/L (range 0.6–1.2610
9/L), respectively (Fig. 1)
(p,0.001). Donor engraftment was confirmed by the ameloginin
gene expression method [42] (not shown).
Effect of heparanase on GVHD
Prolonged survival of mice treated with heparanase. F1
mice were sublethally irradiated (750 cGy) and transplanted with
10610
6 spleen cells from heparanase treated or untreated C57BL/
6 mice (5 mg/mouse/day, i.p. for 3 days). The recipient mice were
injected with heparanase (5 mg/mouse/day, i.p. daily) or saline
from the day of transplantation until day +7. Thus, the 4
experimental groups were as follows: a) Both donor and recipient
mice treated with heparanase; b) Only donor mice treated with
heparanase; c) Only recipient mice treated with heparanase; d)
Both donor and recipient mice treated with saline. Figure 2A
demonstrates a highly significant prolongation in survival when
both the donor and recipient mice were treated with heparanase
(group a) as compared to group (d) where both the donor and
recipient mice received saline alone. A partial effect was achieved
when either the donor or recipient mice received heparanase.
Next, F1 recipient mice were sub-grouped and received different
doses of heparanase (1 mg/mouse/day, 5 mg/mouse/day) for 7
days starting on the day of transplantation, or 35 mg heparanase
per mouse, twice weekly for 5 weeks. Control mice received saline
instead of heparanase. While all mice in the control group died of
GVHD, all mice treated with 35 mg heparanase twice weekly and
the vast majority of mice receiving 1 and 5 mg heparanase daily,
remained alive for .45 days. Mice receiving 1 mg heparanase
displayed mild signs of GVHD (Fig. 2B).
Prolonged survival of transgenic mice over-expressing
heparanase. We investigated the outcome of BMT in
transgenic (hpa-tg) mice over-expressing the heparanase gene in
most tissues [40]. For this purpose, hpa-tg and control host mice
were injected with 10610
6 spleen cells obtained from C57BL/6
mice. Mice were evaluated for the extent of GVHD and survival
Figure 1. Heparanase potentiates engraftment of WBC. F1 mice
were sublethally irradiated (750 cGy) and transplanted intravenously
with 10610
6 spleen cells taken from heparanase (5 mg/mouse/day, i.p.
for 5 days) or saline (control) treated C57BL/6 mice. The recipient mice
were treated with heparanase (5 mg/mouse/day, i.p.) from the day of
transplantation until day +7. Control recipient mice were injected with
saline alone. Each group consisted of 8 mice. Heparanase treatment of
both the donor and recipient mice caused a significant increase in the
mean WBC count on day +14 post transplantation. 1.36610
9/L (range
1.2–1.68610
9/L) (%) vs. 0.48610
9/L (range 0.3–0.74610
9/L) in the
control group (&). Significantly higher WBC counts were maintained in
the heparanase treated group 3 weeks post transplantation. Chimerism
was assessed by the ameloginin gene expression method. Each bar
represents mean 6 SD (n=8 mice) and the experiment was performed
3 times with similar results.
doi:10.1371/journal.pone.0010135.g001
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hair loss and diarrhea. All the donor mice were male and the
recipient mice were females and engraftment was monitored by
ameloginin gene expression [42] (not shown). As demonstrated in
figure 2C, the hpa-tg mice failed to develop clinical signs of GVHD
and all mice survived at least 45 days post transplantation, when
the experiment was terminated. On the other hand, more than
80% of the control mice developed GVHD and died during the
same period of time (Fig. 2C). Similar results were obtained when
the number of injected donor cells was increased to 25610
6,o r
even 50610
6 cells/mouse, further supporting the protective effect
of heparanase generated by the hpa-tg mice (Fig. 2C).
Heparanase regulates T cell function
Reduced activation and killing capacity of splenocytes in
vitro. GVHD is characterized by an attack of alloimmune
donor T-cells on host tissues and organs. CD4
+ cells are polarized
toward the Th1 phenotype and thereby mediate the inflammatory
process through which tissue damage occurs [28,33,34,35,50].
Having demonstrated a protective effect of heparanase against
GVHD in mice, and in an attempt to elucidate the mode of
heparanase action in this process, we investigated its effect on
activation of lymphocytes. For this purpose, mouse splenocytes
were cultured (12 h, 37uC) without or with increasing amounts of
either active (8+50 kDa) or latent (65 kDa) heparanase, and
Figure 2. Effect of heparanase on GVHD. A. Prolonged survival of mice treated with heparanase. Mice were sublethally irradiated
(750 cGy) and transplanted i.v with 10610
6 spleen cells from heparanase treated or un-treated C57BL/6 mice (5 mg/mouse/day, i.p. for 3 days). The
recipient mice were injected with heparanase (5 mg/mouse/day, i.p. daily) from the day of transplantation until day +7, or with saline for the same
period of time. Altogether, 4 experimental groups (10 mice each) were tested: Donor and recipient mice treated with heparanase (N
); Only donor
mice treated with heparanase (%); Only recipient mice treated with heparanase (#); Donor and recipient mice treated with saline alone (D). A
significant prolongation of survival was documented when both the donor and recipient mice were treated with heparanase (N
), as compared to the
control group where both the donor and recipient mice were treated with saline alone (D). In the two other groups, where heparanase was
administered to either the donors (N
) or recipients (%), a partial effect was achieved. B. Mice treated with different doses of heparanase. Mice
were sublethally irradiated (750 cGy) and transplanted with 10610
6 spleen cells from heparanase treated C57BL/6 mice (5 mg/mouse/day, i.p. for 3
days). The recipient mice were sub-grouped with each arm (8 mice each) receiving a different dose of heparanase per day. Injections were given from
the day of transplantation as follows: 1 mg/mouse/day, for 7 days until day +7 post transplantation (%); 5 mg/mouse/day, for 7 days until day +7 post
transplantation (#); 35 mg/mouse twice weekly (D); Both the donor and recipient mice treated with saline alone, as control (N
). All the control mice
died of GVHD. In contrast, all the mice treated with 35 mg heparanase/mouse and all the mice (except one in each group) in the two other groups,
remained alive until the end of the experiment (.45 days). Mice that received 1 mg heparanase/mouse/day exhibited clinical signs of mild GVHD. C.
Transgenic mice over-expressing heparanase. Spleen-derived progenitor cells obtained from C57BL/6 mice were injected with 25610
6 cells/
mouse (n), or 50610
6 cells/mouse (m) into heparanase transgenic (Hpa-tg) and control mice (n=10). All the Hpa-tg mice survived until the end of the
experiment. In contrast, more than 80% of the control mice, receiving either 25610
6 cells/mouse (%), or 50610
6 cells/mouse (#), died of GVHD. The
experiment was performed twice with similar results.
doi:10.1371/journal.pone.0010135.g002
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heparanase to the culture medium resulted in a substantial, dose
dependent decrease in ConA activation and proliferation of the
spleen cells (Fig. 3A). The Active (8+50 kDa) form of heparanase
was more potent than the latent 65 kDa pro-enzyme (Fig. 3A). A
similar decrease in ConA activation was obtained in the absence
or presence of 100 mg/ml of the heparanase inhibitor ST1514
(glycol-split heparin [15,45,46]) (Fig. 3B). Under this condition,
heparanase activity was fully inhibited, further emphasizing that
heparanase enzymatic activity is not required for its inhibition of
lymphocyte activation. In order to verify this finding, we utilized
heparanase in which glutamic acid residues 225 and 343 that
comprise the enzyme active site [43] were point mutated, yielding
an inactive enzyme, as previously described [51]. The inactive
enzyme inhibited the activation of lymphocytes by ConA to an
extent comparable in magnitude to that of active (8 + 50 kDa)
heparanase (Fig. 3B), further substantiating that a non-enzymatic
activity of heparanase is responsible for its inhibition of ConA
induced lymphocytes activation. In a subsequent experiment,
spleen cells were taken from Balb/C mice and reacted against
C57BL/6 splenocytes in a one way mixed lymphocyte culture
(MLC), in the absence or presence of 30 mg/ml latent heparanase.
As demonstrated in figure 3C, latent heparanase markedly
inhibited (,4 fold) the MLC response. Similar results were
obtained using 5 mg/ml of the active enzyme (not shown).
Killing capacity of activated splenocytes. Spleen derived
lymphocytes were subjected to ConA activation and the activated
lymphocytes were then co-cultured with target Yac cells, with or
without addition of active (5 mg/ml) or latent (30 mg/ml)
heparanase, in order to evaluate their killing capacity.
Figure 3. Effect of heparanase on activation of T lymphocytes. A. ConA activation. Mouse spleen cells were isolated and subjected to
activation with ConA in the absence (control) (&) and presence of 10 or 30 mg/ml recombinant latent (65 kDa) ( ) or active (8+50 kDa) (%)
heparanase, followed by measurements of
3H-thymidine incorporation, as described under ‘Materials & Methods’. Addition of heparanase to the
culture medium resulted in a significant (p,0.01) dose dependent decrease in ConA activation and proliferation of the spleen cells. The asterisk (*)
indicates statistically significant differences between the control and the different treatments. B. Heparanase-mediated inhibition of ConA
stimulated T-cell proliferation is independent of its enzymatic activity. Mouse spleen cells were isolated and subjected to activation with
ConA in the absence (control) and presence of active heparanase, active heparanase plus glycol split heparin (100 mg/ml, compound 1514), or
inactive heparanase (point mutated in glutamic residues 225 and 343).
3H-thymidine incorporation was inhibited to a similar extent regardless of
whether the heparanase was enzymatically active or inactive (p,0.001). C. Mixed lymphocyte culture (MLC). One way MLC reaction was
performed in the absence (control) (&) or presence ( )o f3 0mg/ml recombinant latent (65 kDa) heparanase. A marked decrease in activation (
3H-
thymidine incorporation) of Balb/c-derived lymphocytes sensitized against C57BL/6-derived lymphocytes was noted in the heparanase treated
culture (p,0.01). D. Killing capacity of activated T cells. ConA activated splenocytes were co-cultured with target Yac cells in the absence (&)o r
presence ( )o f5mg/ml active (8+50 kDa) or 30 mg/ml latent (65 kDa) heparanase in order to evaluate their killing capacity. Treatment with either
the latent or active forms of heparanase markedly inhibited the ability of the activated lymphocytes to kill their target cells (p,0.01). Each bar
represents mean 6 SD from triplicate wells. All experiments were performed at least three times; variations between different experiments did not
exceed 620%.
doi:10.1371/journal.pone.0010135.g003
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marked reduction (3- and 2-fold, respectively) in the capacity of
the ConA activated lymphocytes to kill their target cells. Thus,
heparanase appears to suppress not only the activation of
lymphocytes, but also their killing capacity (Fig. 3D), resulting in
a robust lymphosuppressive effect.
Effect of heparanase on cytokine production in
vivo. Development of Th1 or Th2 cells from naı ¨ve CD4+ T-
cells is determined by the cytokine milieu during the initial phase
of the immune response. CD4+ T-cells from donor origin with
polarization towards the Th1 phenotype exhibit accelerated
alloimmune activity against components of their target organs,
causing the symptoms observed in GVHD [35]. Increasing the
level of cytokines characteristic of Th2 cells and a parallel decrease
in the amount of Th1-type cytokines, ameliorate the signs and
symptoms of the disease [35]. IL-12 plays a major role in driving
differentiation of uncommitted T-cells towards a Th1 phenotype
[52]. Conversely, IL-4, IL-6 and IL-10 are produced primarily by
Th2 cells [53]. We therefore studied the effect of heparanase on
the Th1/Th2 balance in mice. For this purpose C57BL/6 mice
were subjected to a daily injection of active (8+50 kDa) heparanase
(3 days, 5 mg/mouse/day). Splenocytes were then harvested,
activated with ConA (24 h, 37uC, RPMI + 10% FCS) and the
levels of secreted IL-4, IL-6, IL-10 and IL-12 were determined by
ELISA. The amount of Th2-type cytokines such as IL-4, IL-6 and
IL-10, was increased 25.0, 17.2, and 2.2 fold, respectively,
following exposure of mice to heparanase (p,0.001, Fig. 4A). In
contrast, under the same conditions, there was a marked decrease
(8.3 fold, p,0.01) in the level of IL-12 (Fig. 4A). We also studied
the effect of heparanase on TNF-a and IFN-c. TNF-a promotes
inflammation and its neutralization suppresses a broad spectrum
of inflammatory autoimmune diseases [39,54]. Similarly, IFN-c is
a potent pro-inflammatory cytokine elevated in both acute and
chronic GVHD [55]. The amounts of both TNF-a and IFN-c
secreted by ConA activated splenocytes derived from heparanase
treated C57BL/6 mice were 2-fold lower than those secreted by
splenocytes derived from untreated mice and subjected to ConA
activation (p,0.01, Fig. 4B).
Effect of heparanase on cytokine production in
vitro. Spleen lymphocytes harvested from C57BL/6 mice
were co-activated with IL-2 (24 h, 37uC, RPMI + 10% FCS) in
the presence of latent heparanase (30 mg/ml), or saline alone
(control group). Aliquots of the culture medium were subjected to
ELISA analysis of IL-6, IL-10, and IL-12 levels. The amounts of
secreted IL-6 and IL-10, representing Th2-type cytokines, were
increased by 12.8 and 14.5-fold, respectively (p,0.001, Fig. 4C),
following exposure to heparanase in vitro, as opposed to a marked
decrease (5.8 fold) in the level of IL-12 (p,0.01, Fig. 4C).
Altogether, these results indicate that both active and latent
heparanase exert a direct effect on splenocytes, modulating their
Th-1/Th2 balance.
Discussion
Allogeneic SCT is increasingly used for the treatment of a
growing number of malignant and non-malignant disorders.
However, GVHD remains a major obstacle [30]. Heparanase,
the predominant enzyme degrading heparan sulfate, plays a
significant role in inflammation, exerting both enzymatic and non-
enzymatic activities [9,10,15]. Yet, the involvement of heparanase
in GVHD has not been evaluated. Our results indicate an
important role of heparanase in facilitating engraftment and
suppressing GVHD post SCT, critical to the success of
hematopietic transplantation.
We have demonstrated that heparanase facilitates engraftment
as indicated by a higher WBC counts in the peripheral blood of
the heparanase treated mice, 2 and 3 weeks post transplantation,
as compared to control mice. Degradation of various components
of the subendothelial ECM is mandatory for extravasation and
transmigration of circulating hematopoietic stem and progenitor
cells. Cleavage of HS disintegrates the supramolecular structure of
the subendothelial basement membrane, thereby facilitating trans-
endothelial migration of hematopoietic cells [25], essential for
engraftment. Indeed, Spiegel et al [31] have recently demonstrated
a marked increase in the number of hematopoietic stem cells in the
BM of heparanase over-expressing transgenic (Hpa-tg) mice and
that a limited dose of WBC from the BM of these mice was
sufficient to rescue lethality irradiated recipient mice [31]. This
result further substantiates the relevance of heparanase for
hematopoietic engraftment.
Applying mouse transplantation models, we have demonstrated
up to 100% survival of both heparanase treated and heparanase
over-expressing mice, likely attributed not just to the above
described improved engraftment, but primarily to a marked
suppression of GVHD.
Heparanase was previously demonstrated to facilitate lympho-
cyte invasion through tissue barriers [24,25]. The enzyme has also
been shown to release various growth factors, cytokines and
chemokines sequestered by HS in the ECM, basement membrane
and cell surfaces [16]. The released factors mediate processes such
as angiogenesis and cell proliferation that often accompany the
inflammatory response, including GVHD [16,25]. Recently we
have demonstrated an association between heparanase gene SNPs
and GVHD in patients undergoing allogeneic stem cell transplan-
tation [56]. Discrepancy in heparanase gene SNPs combinations
between recipients and donors was found to be a risk factor for
developing acute GVHD [56]. It was therefore expected that
administration of heparanase to mice in the context of allogeneic
SCT will enhance the allo-inflammatory process through
increased recruitment of T cells to the affected tissue, accelerating
GVHD. In contrast, we observed that administration of
heparanase to the donor and recipient mice resulted in a
significant decrease in the clinical parameters of GVHD and
prolonged survival compared to control saline-treated mice. These
results were further substantiated by using transgenic (hpa-tg) mice
over-expressing heparanase, as recipients of the allogeneic graft.
The survival of these mice was 100%, as opposed to 0–25%
survival (depending on the dose of transplanted stem cells) in the
control mice. Notably, it appears that exogenously added
recombinant heparanase is less effective than the endogenous
enzyme (Hpa-tg mice) in its ability to suppress GVHD, most likely
due to pharmacokinetic considerations.
While heparanase enzymatic activity is traditionally involved in
promoting lymphocyte cell migration and invasion, the currently
observed anti-GVHD effect of heparanase may suggest that a non
catalytic mechanism is responsible. In fact, we have identified
several non-catalytic activities of heparanase (i.e., cell adhesion,
gene transcription, signal transduction) [9,51,57] thought to be
mediated by yet unidentified cell surface receptors [57]. More
recently, we have demonstrated stimulated production and
secretion of cytokines, upon incubation of monocytes with inactive
heparanase (Blich et al., in preparation), further illustrating the
relevance of heparanase non-enzymatic functions to inflammatory
processes and possibly GVHD. Of specific relevance is the up-
regulation of both VEGF-A [58] and VEGF-C [59] in response to
over-expression or exogenous addition of either active or inactive
(double mutated) heparanase. Indeed, inverse correlation between
VEGF levels and the severity of GVHD were reported (patients
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with mild or no GVHD, indicating that higher VEGF levels post-
transplantation may protect against the development of severe
GVHD [60]. To better elucidate the mode of action of heparanase
in the GVHD mouse model, we investigated its effect on T cells in
vitro. Applying the ConA and MLC lymphocyte activation assays,
we have demonstrated a direct inhibitory effect of heparanase,
either the active (8 + 50 kDa) or latent (65 kDa) forms, on
lymphocyte cell activation and proliferation. Moreover, lympho-
cyte activation by ConA was inhibited also following co-
administration of heparanase and a potent inhibitor (non-
anticoagulant glycol split heparin) of its enzymatic activity
[15,45,46], and, even more so, by an inactive enzyme in which
the active site proton donor (Glu-225) and nucleophil (Glu-343)
[43] were replaced by inert residues. Altogether, these results
support the notion that heparanase enzymatic activity is not
required to ameliorate the clinical signs of GVHD.
Historically, acute GVHD has been considered a primarily
Th1/Tc1-type process based on the predominant of cytotoxic T-
cell mediated pathology and increased production of Th1 type
cytokines, including IL-12 and IFNc, while cytokines that polarize
donor T-cells to Th2 (e.g., IL-4, IL-10) can reduce acute GVHD
[33,34,35]. Th2-shifting of lymphocytes is known to be associated
with suppression of disease signs in the GVHD model
[28,33,35,50]. Notably, we have demonstrated that the stimulated
lymphocytes were shifted towards the Th2 phenotype, character-
ized by increased production of IL-4, IL-6 and IL-10, and a
marked decrease in IL-12, TNF-a and IFN-c secretion by the
activated cells. A similar shift was noted in splenocytes derived
from C57BL/6 mice that were treated with heparanase. The
cytokine release assays in vitro were performed with un-separated
lymphocytes, resembling the situation in vivo. These results support
a role for heparanase in determining the polarity status of
lymphocytes in a way that suppresses their ability to promote the
Figure 4. Effect of heparanase on cytokine production. A, B. In vivo. A. C57BL/6 mice were subjected to a daily injection of active (8+50 kDa)
heparanase (3 days, 5 mg/mouse/day) or saline (control). Splenocytes were then harvested, activated with ConA (24 h, 37uC, RPMI + 10% FCS) and
aliquots of the culture medium were subjected to ELISA analysis of IL-4, IL-6, IL-10 and IL-12. The amounts of secreted Th2-type cytokines such as IL-4,
IL-6 and IL-10, were increased following in vivo administration of heparanase (%) vs. saline (&). In contrast, under the same conditions, there was a
marked decrease in the level of IL-12, representing a Th1-associated cytokine. B. TNF-a and IFN-c. C57BL/6mice were subjected to a daily injection of
active (8+50 kDa) heparanase (3 days, 5 mg/mouse/day) or saline (control). Supernatants from ConA activated cells were subjected to ELISA analysis of
TNF-a and IFN-c. The amounts of secreted TNF-a and IFN-c were decreased following administration of heparanase (%) as compared to saline (&). C.
In vitro. C57BL/6derived spleenlymphocytes were harvested and co-activated with IL-2 (24 h, 37uC, RPMI + 10% FCS) in the presence of 65 kDa latent
heparanase (30 mg/ml) (%) or saline (&). Aliquots of the culture medium were subjected to ELISA analysis as above. Each bar represents mean6SD
from triplicate wells. All experiments were performed at least three times; variations between different experiments did not exceed 615%. The
amounts of the secreted Th2-type cytokines IL-6 and IL-10 were increased following exposure to heparanase as compared to saline. In contrast, there
was a marked decrease in the level of IL-12, representing a Th1 cytokine, in cells that were similarly treated with IL-2 and heparanase for 24 h.
doi:10.1371/journal.pone.0010135.g004
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that recently a third T cell subset, Th17, has been recognized and
suggested to contribute to development of GVHD [61]. Thus, the
Th1/Th2 theory may be somewhat oversimplified. The mecha-
nism by which heparanase induces a shift from Th1 toward a Th2
phenotype is not clear. We have previously demonstrated that
heparanase enzymatic activity is involved in shedding of syndecan-
1(sdc-1) [62]. Sdc-1 modulates inflammatory responses possibly via
shifting the Th1/Th2 balance towards a Th2 response, illustrated
by decreased Th1 and higher Th2 cytokine/chemokine expression
in sdc-1 null mice [63,64]. Removal of sdc-1 by heparanase may
thus provide a mechanism for its anti-GVHD protective effect.
Alternatively, the observed anti-GVHD effect of heparanase may
be mediated by its non-enzymatic functions, as mentioned above,
possibly through binding to and activation of a putative cell surface
receptor [57]. Apart of HSPGs, several cell surface proteins have
been shown to bind heparanase and mediate its uptake. These
include mannose 6-phosphate receptor (MPR) and low density
lipoprotein receptor-related protein (LRP) [65,66] which poten-
tially can mediate heparanase signaling and non-enzymatic effects.
The existence of cell surface heparanase receptor(s) is supported by
binding experiment, reinforcing the notion that while HSPGs
serve as low affinity, high abundant binding sites, heparanase also
associates with high affinity, low abundant cell surface receptor(s)
[67]. A first indication for the protein nature of this receptor and
its molecular weight emerged from cross-linking experiments
applying several cell types and revealing two distinct complexes
representing 110 and 150 kDa proteins associated with the
heparanae C-terminus domain (C-domain) [57]. Clearly, identi-
fication and characterization of a cell surface receptor for
heparanase constitutes a most relevant challenge for progress in
the field. Regardless of its mode of action, the observed effect of
heparanase on engraftment, its ability to ameliorate GVHD and
improve survival post SCT in mice may be of clinical significance
serving as a new strategy, improving the outcome of SCT.
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